• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr236Ter (c.708C>A); Zygosity=Unspecified (PubMed=16203773).
  

PubMed=16035614; DOI=10.1007/s10585-004-6918-5
Robert Mandic, Thomas Ludwig, Hans Oberleithner, Jochen Alfred Werner;
Evaluation of head and neck squamous cell carcinoma invasiveness by the electrical resistance breakdown assay.
Clin. Exp. Metastasis 21:699-704(2004)

PubMed=16203773; DOI=10.1158/1078-0432.CCR-05-0378
Robert Mandic, Chantal J. Schamberger, Julia F. Muller, Matthias Geyer, Li Zhu, Thomas E. Carey, Reidar Grenman, Anja A. Dunne, Jochen Alfred Werner;
Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
Clin. Cancer Res. 11:6845-6852(2005)

PubMed=17312569; DOI=10.1002/hed.20478
Charles J. Lin, Jennifer Rubin Grandis, Thomas E. Carey, Susanne M. Gollin, Theresa L. Whiteside, Wayne M. Koch, Robert Louis Ferris, Stephen Y. Lai;
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=19414362
Robert Mandic, Chantal J. Rodgarkia-Dara, Vanessa Krohn, Susanne Wiegand, Reidar Grenman, Jochen Alfred Werner;
Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Anticancer Res. 29:1181-1187(2009)

DOI=10.1158/1538-7445.AM2020-507
Maria K. Kondratyev, Aleksandra Pesic, Anna Dvorkin-Sheva, Troy Ketela, Jason Moffat, Marianne Koritzinsky, Bradly G. Wouters;
Repurposing of FDA approved drugs for treatment of metastatic HNSCC.
Cancer Res. 80 Suppl. 16:507-507(2020)